Although CCDC124 has not been reported to be associated with antineoplastic drug resistance, MLKL is a pseudokinase that plays a pivotal role in tumor necrosis factor‐induced necroptosis and mediates the antimicrobial peptide HPA3P‐induced necrotic death in colon cancer.47 Moreover, Sun et al have developed a nanoscale cationic liposome system encapsulating MLKL‐pDNA, SMAC mimetic, and zVAD to solve the multidrug resistance in colon cancer cells.48 These previous researches and our findings implied that MLKL could be a potential therapeutic target for FOLFOX‐resistant metastatic CRC patients. The gene discussed is MLKL; the disease is malignant colon neoplasm.